Navigation Links
NaZura BioHealth Spun-out from Elcelyx Therapeutics to Advance Lovidia for Weight Management
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that it has formed NaZura BioHealth, a separate company established to focus on the development of Gut Sensory Modulators (GSM) including lead product Lovidia™, a dietary supplement for weight management. Elcelyx retains pharmaceutical product candidate NewMet™, the company's proprietary delayed-release formulation of metformin for the treatment of patients with Type 2 diabetes. Elcelyx has funded NaZura with a credit line of $5 million, which will be used for clinical development of Lovidia and pre-commercial activities.

(Logo: http://photos.prnewswire.com/prnh/20130904/LA73683LOGO)

"We are separating the Lovidia and NewMet assets in order to maximize their value as we approach critical development milestones," said Alain D. Baron, M.D., president and chief executive officer of both NaZura BioHealth and Elcelyx Therapeutics. "NaZura BioHealth will commercialize Lovidia, a one-of-a-kind weight loss product with launch planned for early second quarter 2014, and Elcelyx Therapeutics will continue to advance NewMet for Type 2 diabetes."

Lovidia, a dietary supplement, is being developed with the level of rigor typical of pharmaceutical products. An early Lovidia prototype demonstrated statistically significant and progressive weight loss through 16 weeks in a randomized, placebo-controlled, double-blind clinical study. In 121 evaluable overweight or obese subjects, three times as many people lost 5% of their body weight compared to placebo. This was accomplished without diet or exercise modification and the tolerability and safety profile of the prototype was similar to placebo. In other short-term studies, preliminary formulations of Lovidia increased the body's food-driven production of natural satiety and gluco-regulatory gut hormones twofold; with the same number of calories, subjects had twice the satiety signal.

An optimized version of Lovidia is now being readied for market. It is expected that this optimized product will produce greater weight loss than that seen with the prototype. A 16-week clinical study using the optimized Lovidia product is now underway. This placebo-controlled, double-blind weight loss study in 240 overweight and obese subjects is fully enrolled with results expected in the fourth quarter of 2013.

Lovidia is a proprietary mix of dietary ingredients designated by the U.S. Food and Drug Administration as Generally Recognized as Safe (GRAS) and FDA-approved food additives.

NaZura BioHealth and Elcelyx Therapeutics share the same board of directors, including Ralph Christoffersen, Ph.D., Morgenthaler Ventures (chairman); Alain D. Baron, M.D.; Rick Barry, GSM Fund LLC; Brook Byers, Kleiner Perkins Caufield & Byers; Jim Glasheen, Ph.D., Technology Partners; Ginger L. Graham, former President and CEO, Amylin Pharmaceuticals.

About NaZura BioHealth, Inc.
NaZura BioHealth is developing consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) technology. GSMs are delivered to the lower gut where they intensify the body's natural food-driven signals that trigger a sense of fullness and facilitate glucose regulation. NaZura plans to commercialize its lead product, Lovidia™, a dietary supplement for weight management, in early second quarter 2014. For more information, visit www.NaZuraBio.com.

About Elcelyx Therapeutics, Inc.
Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet™ for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity.  Elcelyx is based in San Diego, CA. For more information, visit www.Elcelyx.com.


'/>"/>
SOURCE NaZura BioHealth, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
2. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
3. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
4. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
5. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
6. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
7. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
8. PTC Therapeutics to Present at Upcoming Investor Conferences
9. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
10. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
11. Echo Therapeutics Announces Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 27, 2016 According to the ... is driving ambulatory blood pressure monitoring system market growth. ... their ability to respond to different pressure rates, leading ... lead to various cardiovascular disorders such as heart failure, ... diseases are growing in prevalence each year. WHO estimates ...
(Date:5/26/2016)... ALBANY, New York , May 26, 2016 ... Transparency Market Research "Medical Waste Management Market - U.S. Industry ... the medical waste management market in the U.S. was valued ... expand at a CAGR of 3.4% from 2015 to 2023 ... report provides exhaustive analysis of current and emerging needle free ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/30/2016)... ... 30, 2016 , ... Shaolin Institute officially starts the annual ... intensive summer training camp starts on June 17th on Shaolin Institute Atlanta Campus. ... a fun and unique experience with an opportunity to learn KungFu martial arts ...
(Date:5/28/2016)... (PRWEB) , ... May 28, 2016 , ... SuperCloset is ... all too well the day to day issues, struggles and obstacles veterans’ need to ... Helping Veterans Grow Project provides active or retired military veteran(s) with a donated SuperCloset ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of American adults ... that bariatric surgery has received increased attention in recent years, as an article ... comes to weight loss, most people are familiar with the basic requirements of maintaining ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
Breaking Medicine News(10 mins):